Advertisement

Journal of Molecular Medicine

, Volume 95, Issue 10, pp 1043–1052 | Cite as

Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration

  • Adeline A. Lau
  • Kim M. Hemsley
Review

Abstract

The mucopolysaccharidoses (MPS) are a subgroup of lysosomal storage disorders that are caused by mutations in the genes involved in glycosaminoglycan breakdown. Multiple organs and tissues are affected, including the central nervous system. At present, hematopoietic stem cell transplantation and enzyme replacement therapies are approved for some of the (non-neurological) MPS. Treatments that effectively ameliorate the neurological aspects of the disease are being assessed in clinical trials. This review will focus on the recent outcomes and planned viral vector-mediated gene therapy clinical trials, and the pre-clinical data that supported these studies, for MPS-I (Hurler/Scheie syndrome), MPS-II (Hunter syndrome), and MPS-IIIA and -IIIB (Sanfilippo syndrome).

Keywords

Gene therapy Viral vectors Lysosomal storage disease Mucopolysaccharidosis Central nervous system 

Notes

Acknowledgements

The authors have received funding for their research from the Australian National Health and Medical Research Council of Australia, the Women’s and Children’s Hospital Foundation (Australia), the Sanfilippo Children’s Research Foundation (Canada), Swiss Sanfilippo Foundation, Alliance Sanfilippo, the National MPS Society (USA), the Isaac Foundation, Lysogene, and Shire Human Genetic Therapies. The funding sources did not have any role in the writing of this review or in the decision to submit it for publication.

References

  1. 1.
    Vitner EB, Platt FM, Futerman AH (2010) Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem 285:20423–20427CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, Pinto E, Silva E, Rocha S, Marcao A et al (2004) Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 12:87–92CrossRefPubMedGoogle Scholar
  3. 3.
    Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249–254CrossRefPubMedGoogle Scholar
  4. 4.
    Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105:151–156CrossRefPubMedGoogle Scholar
  5. 5.
    Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, Yeh HY, Chao MC, Lin SJ, Kitagawa T et al (2009) Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat 30:1397–1405CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79:31–40CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Applegarth DA, Toone JR, Lowry RB (2000) Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 105:e10CrossRefPubMedGoogle Scholar
  8. 8.
    Scott HS, Anson DS, Orsborn AM, Nelson PV, Clements PR, Morris CP, Hopwood JJ (1991) Human alpha-L-iduronidase: cDNA isolation and expression. Proc Natl Acad Sci U S A 88:9695–9699CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wilson PJ, Morris CP, Anson DS, Occhiodoro T, Bielicki J, Clements PR, Hopwood JJ (1990) Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA. Proc Natl Acad Sci U S A 87:8531–8535CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Scott HS, Blanch L, Guo X-H, Freeman VC, Orsborn A, Baker E, Sutherland GR, Morris P, Hopwood JJ (1995) Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome. Nat Genet 11:465–467CrossRefPubMedGoogle Scholar
  11. 11.
    Weber B, Blanch L, Clements PR, Scott HS, Hopwood JJ (1996) Cloning and expression of the gene involved in Sanfilippo B syndrome (Mucopolysaccharidosis III B). Hum Mol Genet 5:771–777CrossRefPubMedGoogle Scholar
  12. 12.
    Zhao HG, Li HH, Bach G, Schmidtchen A, Neufeld EF (1996) The molecular basis of Sanfilippo syndrome type B. Proc Natl Acad Sci U S A 93:6101–6105CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hopwood JJ, Morris CP (1990) The mucopolysaccharidoses. Diagnosis, molecular genetics and treatment. Mol Biol Med 7:381–404PubMedGoogle Scholar
  14. 14.
    Dahms NM, Lobel P, Kornfeld S (1989) Mannose 6-phosphate receptors and lysosomal enzyme targeting. J Biol Chem 264:12115–12118PubMedGoogle Scholar
  15. 15.
    Hopwood JJ, Brooks DA (1997) An introduction to the basic science and biology of the lysosome and storage disorders. In: Appelgarth DA (ed) organelle diseases chapman and hall Medical, London, pp. 7-35Google Scholar
  16. 16.
    Kornfeld S (1992) Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu Rev Biochem 61:307–330CrossRefPubMedGoogle Scholar
  17. 17.
    Brown WJ, Goodhouse J, Farquhar MG (1986) Mannose-6-phosphate receptors for lysosomal enzymes cycle between the Golgi complex and endosomes. J Cell Biol 103:1235–1247CrossRefPubMedGoogle Scholar
  18. 18.
    Willingham MC, Pastan IH, Sahagian GG, Jourdian GW, Neufeld EF (1981) Morphologic study of the internalization of a lysosomal enzyme by the mannose 6-phosphate receptor in cultured Chinese hamster ovary cells. Proc Natl Acad Sci U S A 78:6967–6971CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Hasilik A (1992) The early and late processing of lysosomal enzymes: proteolysis and compartmentation. Experientia 48:130–151CrossRefPubMedGoogle Scholar
  20. 20.
    Smith LG, Weissman IL, Heimfeld S (1991) Clonal analysis of hematopoietic stem-cell differentiation in vivo. Proc Natl Acad Sci U S A 88:2788–2792CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hobbs JR, Hugh-Jones K, Barrett AJ, Byrom N, Chambers D, Henry K, James DC, Lucas CF, Rogers TR, Benson PF et al (1981) Reversal of clinical features of Hurler’s disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 2:709–712CrossRefPubMedGoogle Scholar
  22. 22.
    Aldenhoven M, Wynn RF, Orchard PJ, O'Meara A, Veys P, Fischer A, Valayannopoulos V, Neven B, Rovelli A, Prasad VK et al (2015) Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood 125:2164–2172CrossRefPubMedGoogle Scholar
  23. 23.
    Krivit W (2004) Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin Immun 26:119–132CrossRefGoogle Scholar
  24. 24.
    Yamada Y, Kato K, Sukegawa K, Tomatsu S, Fukuda S, Emura S, Kojima S, Matsuyama T, Sly WS, Kondo N et al (1998) Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619v mutation. Bone Marrow Transplant 21:629–634CrossRefPubMedGoogle Scholar
  25. 25.
    Montano AM, Lock-Hock N, Steiner RD, Graham BH, Szlago M, Greenstein R, Pineda M, Gonzalez-Meneses A, Coker M, Bartholomew D et al (2016) Clinical course of sly syndrome (mucopolysaccharidosis type VII). J Med Genet. doi: 10.1136/jmedgenet-2015-103322
  26. 26.
    Guffon N, Bertrand Y, Forest I, Fouilhoux A, Froissart R (2009) Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr 154:733–737CrossRefPubMedGoogle Scholar
  27. 27.
    Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith JE (1999) Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 22:638–648CrossRefPubMedGoogle Scholar
  28. 28.
    Hoogerbrugge PM, Brouwer OF, Bordigoni P, Ringden O, Kapaun P, Ortega JJ, O'Meara A, Cornu G, Souillet G, Frappaz D et al (1995) Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation Lancet 345:1398–1402Google Scholar
  29. 29.
    Shapiro EG, Lockman LA, Balthazor M, Krivit W (1995) Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis 18:413–429CrossRefPubMedGoogle Scholar
  30. 30.
    Fox JE, Volpe L, Bullaro J, Kakkis ED, Sly WS (2015) First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient. Mol Genet Metab 114:203–208CrossRefPubMedGoogle Scholar
  31. 31.
    Munoz-Rojas MV, Vieira T, Costa R, Fagondes S, John A, Jardim LB, Vedolin LM, Raymundo M, Dickson PI, Kakkis E et al (2008) Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A 146A:2538–2544CrossRefPubMedGoogle Scholar
  32. 32.
    Muenzer J, Hendriksz CJ, Fan Z, Vijayaraghavan S, Perry V, Santra S, Solanki GA, Mascelli MA, Pan L, Wang N et al (2016) A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med 18:73–81CrossRefPubMedGoogle Scholar
  33. 33.
    Jones SA, Breen C, Heap F, Rust S, de Ruijter J, Tump E, Marchal JP, Pan L, Qiu Y, Chung JK et al (2016) A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. Mol Genet Metab 118:198–205CrossRefPubMedGoogle Scholar
  34. 34.
    Beutler E (2006) Lysosomal storage diseases: natural history and ethical and economic aspects. Mol Genet Metab 88:208–215CrossRefPubMedGoogle Scholar
  35. 35.
    Goldblatt J, Fletcher JM, McGill J, Szer J, Wilson M (2011) Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia. Blood Cells Mol Dis 46:107–110CrossRefPubMedGoogle Scholar
  36. 36.
    Chen F, Vitry S, Hocquemiller M, Desmaris N, Ausseil J, Heard JM (2006) alpha-L-Iduronidase transport in neurites. Mol Genet Metab 87:349–358CrossRefPubMedGoogle Scholar
  37. 37.
    Passini MA, Lee EB, Heuer GG, Wolfe JH (2002) Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J Neurosci 22:6437–6446PubMedGoogle Scholar
  38. 38.
    Hennig AK, Ogilvie JM, Ohlemiller KK, Timmers AM, Hauswirth WW, Sands MS (2004) AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS VII mice. Mol Ther 10:106–116CrossRefPubMedGoogle Scholar
  39. 39.
    Sands MS, Davidson BL (2006) Gene therapy for lysosomal storage diseases. Mol Ther 13:839–849CrossRefPubMedGoogle Scholar
  40. 40.
    Byrne BJ, Falk DJ, Clement N, Mah CS (2012) Gene therapy approaches for lysosomal storage disease: next-generation treatment. Hum Gene Ther 23:808–815CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Aronovich EL, Bell JB, Belur LR, Gunther R, Koniar B, Erickson DC, Schachern PA, Matise I, McIvor RS, Whitley CB et al (2007) Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses. J Gene Med 9:403–415CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Zolotukhin S (2005) Production of recombinant adeno-associated virus vectors. Hum Gene Ther 16:551–557CrossRefPubMedGoogle Scholar
  43. 43.
    Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, Hunter LA (1991) Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 10:3941–3950PubMedPubMedCentralGoogle Scholar
  44. 44.
    Baum C, Kustikova O, Modlich U, Li Z, Fehse B (2006) Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther 17:253–263CrossRefPubMedGoogle Scholar
  45. 45.
    McCown TJ (2005) Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther 5:333–338CrossRefPubMedGoogle Scholar
  46. 46.
    Mastakov MY, Baer K, Symes CW, Leichtlein CB, Kotin RM, During MJ (2002) Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J Virol 76:8446–8454CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6:1574–1583CrossRefPubMedGoogle Scholar
  48. 48.
    Srivastava A (2016) In vivo tissue-tropism of adeno-associated viral vectors. Curr Opin Virol 21:75–80CrossRefPubMedGoogle Scholar
  49. 49.
    Hoggan MD, Blacklow NR, Rowe WP (1966) Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci U S A 55:1467–1474CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Samulski RJ, Berns KI, Tan M, Muzyczka N (1982) Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A 79:2077–2081CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ (2002) Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76:791–801CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier PJ, Mandel RJ, Muzyczka N (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10:302–317CrossRefPubMedGoogle Scholar
  53. 53.
    Markakis EA, Vives KP, Bober J, Leichtle S, Leranth C, Beecham J, Elsworth JD, Roth RH, Samulski RJ, Redmond DE Jr (2010) Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. Mol Ther 18:588–593CrossRefPubMedGoogle Scholar
  54. 54.
    Sondhi D, Hackett NR, Peterson DA, Stratton J, Baad M, Travis KM, Wilson JM, Crystal RG (2007) Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther 15:481–491CrossRefPubMedGoogle Scholar
  55. 55.
    Cearley CN, Wolfe JH (2006) Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 13:528–537CrossRefPubMedGoogle Scholar
  56. 56.
    Thwaite R, Pages G, Chillon M, Bosch A (2015) AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy. Gene Ther 22:196–201CrossRefPubMedGoogle Scholar
  57. 57.
    Liu Q, Huang W, Zhang H, Wang Y, Zhao J, Song A, Xie H, Zhao C, Gao D, Wang Y (2014) Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors. Gene Ther 21:732–738CrossRefPubMedGoogle Scholar
  58. 58.
    Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27:59–65CrossRefPubMedGoogle Scholar
  59. 59.
    Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM, Fyfe J, Moullier P, Colle MA, Barkats M (2009) Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17:1187–1196CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Schuster DJ, Dykstra JA, Riedl MS, Kitto KF, Belur LR, McIvor RS, Elde RP, Fairbanks CA, Vulchanova L (2014) Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front Neuroanat 8:42PubMedPubMedCentralGoogle Scholar
  61. 61.
    Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ (2011) Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19:1058–1069CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Winner LK, Beard H, Hassiotis S, Lau AA, Luck AJ, Hopwood JJ, Hemsley KM (2016) A pre-clinical study evaluating AAVrh10-based gene therapy for Sanfilippo syndrome. Hum Gene Ther 27:363–375CrossRefPubMedGoogle Scholar
  63. 63.
    Tardieu M, Zerah M, Husson B, de Bournonville S, Deiva K, Adamsbaum C, Vincent F, Hocquemiller M, Broissand C, Furlan V et al (2014) Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum Gene Ther 25:506–516CrossRefPubMedGoogle Scholar
  64. 64.
    Cressant A, Desmaris N, Verot L, Brejot T, Froissart R, Vanier MT, Maire I, Heard JM (2004) Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J Neurosci 24:10229–10239CrossRefPubMedGoogle Scholar
  65. 65.
    Ellinwood NM, Ausseil J, Desmaris N, Bigou S, Liu S, Jens JK, Snella EM, Mohammed EE, Thomson CB, Raoul S et al (2011) Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther 19:251–259CrossRefPubMedGoogle Scholar
  66. 66.
    Unknown (2016) Intra-cerebral gene therapy for Sanfilippo type B syndrome.Google Scholar
  67. 67.
    Unknown (2015) Positive Topline Results Announced from Phase I/II Trial in Sanfilippo B Syndrome Patients Using uniQure’s Novel AAV5-Based Gene Therapy, Globe Newswire, Amsterdam, the NetherlandsGoogle Scholar
  68. 68.
    Hinderer C, Bell P, Gurda BL, Wang Q, Louboutin JP, Zhu Y, Bagel J, O'Donnell P, Sikora T, Ruane T et al (2014) Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I. Mol Ther 22:2018–2027CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Bell P, Gurda B, Zhu Y, Sikora T, Ruane T, O'Donnell P, Haskins ME, Wilson JM (2015) Evaluating the impact of systemic AAV9.cIDUA administration on brain pathology in MPS I dogs. Mol Genet Metab 114:S25CrossRefGoogle Scholar
  70. 70.
    Hinderer C, Bell P, Louboutin JP, Zhu Y, Yu H, Lin G, Choa R, Gurda BL, Bagel J, O'Donnell P et al (2015) Neonatal systemic AAV induces tolerance to CNS gene therapy in MPS I dogs and nonhuman primates. Mol Ther 23:1298–1307CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Unknown (2015) ReGenXBio licenses key technologies from University of Pennsylvania and University of Minnesota for the development of treatments for MPS I and MPS II, REGENXBIO, Washington, DCGoogle Scholar
  72. 72.
    Motas S, Haurigot V, Garcia M, Marco S, Ribera A, Roca C, Sanchez X, Sanchez V, Molas M, Bertolin J et al (2016) CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome). JCI Insight 1:e86696CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Fu H, Zaraspe K, Meadows A, Camboni M, McCarty DM (2016) Functional benefits of systemic rAAV9-hids gene delivery in MPS II mouse model. Mol Genet Metab 117:S47CrossRefGoogle Scholar
  74. 74.
    Unknown (2016) Esteve and UAB expand their research to two new gene therapies for Sanfilippo B syndrome and Hunter syndrome, PRNewswire, Barcelona.Google Scholar
  75. 75.
    Unknown (2016) FDA grants rare pediatric disease designation to REGENXBIO’s RGX-121 gene therapy for the treatment of mucopolysaccharidosis type II (MPS II), Globe Newswire, Rockville, MD.Google Scholar
  76. 76.
    McCarty DM, Zaraspea K, Murreya D, Warea T, Fu H (2014) Functional correction and reversal of MPS IIIA in a mouse model by an intravenous hSGSH gene delivery using a self-complementary AAV9 vector. Mol Genet Metab 111:S75CrossRefGoogle Scholar
  77. 77.
    Ruzo A, Marco S, Garcia M, Villacampa P, Ribera A, Ayuso E, Maggioni L, Mingozzi F, Haurigot V, Bosch F (2012) Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer. Hum Gene Ther 23:1237–1246CrossRefPubMedGoogle Scholar
  78. 78.
    Haurigot V, Marco S, Ribera A, Garcia M, Ruzo A, Villacampa P, Ayuso E, Anor S, Andaluz A, Pineda M et al (2013) Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest 123:3254–3271CrossRefPubMedCentralGoogle Scholar
  79. 79.
    Unknown (2016) Abeona therapeutics announces FDA allowance of investigational new drug (IND) for systemic AAV phase 1/2 clinical study with ABO-102 gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA), Marketwired, New York, NY and Cleveland, OHGoogle Scholar
  80. 80.
    Unknown (2016) Abeona therapeutics announces initial European regulatory approvals for phase 1/2 gene therapy clinical studies for patients with Sanfilippo syndromes type A (MPS IIIA) and type B (MPS IIIB), Marketwired New York, NY and Cleveland, OHGoogle Scholar
  81. 81.
    Unknown (2017) Abeona therapeutics announces top-line data for ABO-102 phase 1/2 MPS IIIA gene therapy trial at ASGCT, Globe Newswire, New York, NY and Cleveland, OHGoogle Scholar
  82. 82.
    Unknown (2017) Abeona therapeutics provides update from ABO-102 phase 1/2 MPS IIIA clinical trial at the 13th Annual WORLDSymposium™ 2017, Globe Newswire New York, NY and Cleveland, OHGoogle Scholar
  83. 83.
    Fu H, Dirosario J, Killedar S, Zaraspe K, McCarty DM (2011) Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther 19:1025–1033CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Meadows AS, Duncan FJ, Camboni M, Waligura K, Montgomery CL, Zaraspe K, Naughton BJ, Bremer WG, Shilling C, Walker C et al (2015) A GLP-compliant toxicology and biodistribution study: systemic delivery of a rAAV9 vector for the treatment of mucopolysaccharidosis IIIB. Hum Gene Ther Clin Dev 26:228–242CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Murrey DA, Naughton BJ, Duncan FJ, Meadows AS, Ware TA, Campbell KJ, Bremer WG, Walker CM, Goodchild L, Bolon B et al (2014) Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates. Hum Gene Ther Clin Dev 25:72–84CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Ribera A, Haurigot V, Garcia M, Marco S, Motas S, Villacampa P, Maggioni L, Leon X, Molas M, Sanchez V et al (2015) Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy. Hum Mol Genet 24:2078–2095CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Lysosomal Diseases Research Unit, Nutrition and Metabolism ThemeSouth Australian Health and Medical Research Institute (SAHMRI)AdelaideAustralia

Personalised recommendations